Premium
Selective Antibacterial Activity of Patchouli Alcohol Against Helicobacter pylori Based on Inhibition of Urease
Author(s) -
Yu XiaoDan,
Xie JianHui,
Wang YongHong,
Li YuCui,
Mo ZhiZhun,
Zheng YiFeng,
Su JiYan,
Liang Yeer,
Liang JinZhi,
Su ZiRen,
Huang Ping
Publication year - 2015
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5227
Subject(s) - urease , helicobacter pylori , chemistry , antibacterial activity , dithiothreitol , uncompetitive inhibitor , bacteria , antibacterial agent , microbiology and biotechnology , enzyme , biochemistry , biology , non competitive inhibition , antibiotics , genetics
The aim of this study is to evaluate the antibacterial activity and urease inhibitory effects of patchouli alcohol (PA), the bioactive ingredient isolated from Pogostemonis Herba, which has been widely used for the treatment of gastrointestinal disorders. The activities of PA against selected bacteria and fungi were determined by agar dilution method. It was demonstrated that PA exhibited selective antibacterial activity against Helicobacter pylori , without influencing the major normal gastrointestinal bacteria. Noticeably, the antibacterial activity of PA was superior to that of amoxicillin, with minimal inhibition concentration value of 78 µg/mL. On the other hand, PA inhibited ureases from H . pylori and jack bean in concentration‐dependent fashion with IC 50 values of 2.67 ± 0.79 mM and 2.99 ± 0.41 mM, respectively. Lineweaver‐Burk plots indicated that the type of inhibition was non‐competitive against H . pylori urease whereas uncompetitive against jack bean urease. Reactivation of PA‐inactivated urease assay showed DL‐dithiothreitol, the thiol reagent, synergistically inactivated urease with PA instead of enzymatic activity recovery. In conclusion, the selective H . pylori antibacterial activity along with urease inhibitory potential of PA could make it a possible drug candidate for the treatment of H . pylori infection. Copyright © 2014 John Wiley & Sons, Ltd.